Comparative analysis of influence of calcium antagonist and p-blocker on thrombocytic activity in hypertensive patients with metabolic syndrome

The work objective is to conduct a comparative analysis of Amlodipinum and Nebivololum influence on thrombocytic hemostasis. Materials and Methods. During clinical trials Amlodipinum was assigned to 25 patients (3 months, 10 mg/day) and Nebivololum to 21 patients (5 mg/day). Dynamics of anthropometric parameters, blood lipids, lipid peroxidation in plasma and thrombocytes, antioxidant protection of liquid blood and blood platelets, and also aggregative and intravascular activity of thrombocytes were estimated. The results obtained were tested using Student's t-test and the system of multiple-factor analysis. Results and Discussion. Amlodipinum administration for hypertensive patients with metabolic syndrome has a more positive effect on peroxidation syndrome and improves thrombocytic function better than Nebivololum. Long-term administration of Amlodipinum can fix the results obtained. In order to decrease body weight in hypertensive patients with arterial and metabolic syndrome it is necessary to combine both Amlodipinum and drug-free modalities.